2024
Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction
Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction. European Journal Of Heart Failure 2024, 26: 1524-1538. PMID: 38700986, DOI: 10.1002/ejhf.3263.Peer-Reviewed Original ResearchConceptsVisual analogue scaleEjection fractionEQ-5D-5L visual analogue scaleHealth-related quality of lifeIndex scorePatient-level pooled analysisComposite of cardiovascular deathQuality of lifeSafety of dapagliflozinEffects of dapagliflozinReduced ejection fractionAssociated with better outcomesPrevalence of comorbiditiesEuroQol 5-dimension questionnaireMeasures of health-related quality of lifePatient self-reportDAPA-HFWorsening HFVAS scoreClinical characteristicsAtrial fibrillationComposite outcomeHeart failurePooled analysisAnalogue scale
2023
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
Butt J, Jering K, DE Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Jhund P, Køber L, Kosiborod M, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Langkilde A, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon S, McMurray J. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. Journal Of Cardiac Failure 2023, 30: 436-448. PMID: 38104937, DOI: 10.1016/j.cardfail.2023.08.027.Peer-Reviewed Original ResearchConceptsHistory of sleep apneaPrevalence of sleep apneaEffects of dapagliflozinSleep apneaWorsening HF eventsDAPA-HFAssociated with higher ratesHeart failureClinical outcomesEjection fractionPooled analysisComposite of worsening HFEffects of HF therapiesPrimary outcomeHF eventsDELIVER trialBenefits of dapagliflozinDAPA-HF trialAssociated with outcomePrimary endpointHF therapyHigher ratesHF phenotypesApneaTreatment optionsDapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireActivity limitation scoresEffect of dapagliflozinLimitation scoresSocial activity limitationsHeart failureActivity limitationsDAPA-HF trialReduced ejection fractionProportion of patientsActivity limitation domainLimitation domainEjection fractionPhysical functionChronic diseasesDapagliflozinPatientsHealth statusPlaceboMixed-effects modelsMonthsBaselineComplete dataScoresSocial limitations